符合与不符合USPSTF筛查标准的肺癌患者5年总生存分析
这项前瞻性观察队列研究纳入8739例50-80岁、吸烟≥30包年的肺癌患者,比较符合USPSTF筛查标准者与不符合者(长期戒烟≥15年或年龄50-54岁)的5年总生存。结果显示长期戒烟者和年轻组与USPSTF组的5年总生存均无显著差异,提示扩大筛查标准可能使这两个亚组获益。
要点
- 长期戒烟≥15年的肺癌患者5年总生存与符合USPSTF标准者无显著差异。
- 年龄50-54岁但其他条件符合者的5年总生存与USPSTF组无显著差异。
- 扩大USPSTF筛查标准纳入这两个亚组可能实现更早发现并改善生存。
核心结论
- 诊断前戒烟≥15年者及比筛查年龄下限小最多5岁但其他条件符合者,死亡风险与完全符合USPSTF标准者相似。
- 扩大USPSTF筛查标准纳入这两个亚组可能实现更早发现肺癌并改善生存结局。
研究设计与样本
- 前瞻性观察队列研究,纳入美国Mayo Clinic医院队列和Olmsted County社区队列。
- 纳入50-80岁、吸烟史≥30包年的肺癌患者,包括当前吸烟者和戒烟≤30年的既往吸烟者。
- 主要结局为诊断后5年总生存,比较符合USPSTF标准组与不符合组(长期戒烟者或年轻年龄组)。
主要发现
- 5年总生存:长期戒烟者27%(95% CI 25-30),年轻年龄组22%(95% CI 19-25),USPSTF组23%(95% CI 22-24)。
临床怎么用
- 对于戒烟≥15年或年龄50-54岁但其他条件符合USPSTF标准的肺癌高危个体,应考虑筛查可能带来的早期发现获益。
- 临床评估肺癌筛查资格时,不应仅因戒烟超过15年或年龄略低于55岁而排除高危吸烟者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The US Preventive Services Task Force (USPSTF) recommends lung cancer screening among individuals aged 55-80 years with a 30 pack-year cigarette smoking history and, if they are former smokers, those who quit within the past 15 years. Our previous report found that two-thirds of newly diagnosed patients with lung cancer do not meet these criteria; they are reported to be either long-term quitters (≥15 years since quitting) or from a younger age group (age 50-54 years). We aimed to assess survival outcomes in these two subgroups. METHODS: For this prospective, observational cohort study we identified and followed up patients aged 50-80 years with lung cancer, with a smoking history of 30 pack-years or more, and included both current smokers and former smokers who quit within the past 30 years. We identified patients from two cohorts in the USA: a hospital cohort (Mayo Clinic, Rochester, MN) and a community cohort (Olmsted County, MN). Patients were divided into those meeting USPSTF criteria (USPSTF group) versus those not meeting USPSTF criteria (long-term quitters or the younger age group). The main outcome was overall survival at 5 years after diagnosis. 5-year overall survival was analysed with and without matching age and pack-years smoked for long-term quitters. The USPSTF group was subdivided into two age subgroups (55-69 years and 70-80 years) for multivariable regression analysis. FINDINGS: Between Jan 1, 1997, and Dec 31, 2017, 8739 patients with lung cancer were identified and followed up. Median follow-up was 6·5 (IQR 3·8-10·0) years, and median overall survival was 16·9 months (95% CI 16·2-17·5). 5-year overall survival was 27% (95% CI 25-30) in long-term quitters, 22% (19-25) in the younger age group, and 23% (22-24) in the USPSTF group. In both cohorts, 5-year overall survival did not differ significantly between long-term quitters and the USPSTF group (hospital cohort: hazard ratio [HR] 1·02 [95% CI 0·94-1·10]; p=0·72; community cohort: 0·97 [0·75-1·26]; p=0·82); matched analysis showed similar results in both cohorts. 5-year overall survival also did not differ significantly between the younger age group and the USPSTF group in both cohorts (hospital cohort: HR 1·16 [95% CI 0·98-1·38], p=0·08; community cohort: 1·16 [0·74-1·82]; p=0·52); multivariable regression analyses stratified by age group yielded similar findings. INTERPRETATION: Patients with lung cancer who quit 15 or more years before diagnosis and those who are up to 5 years younger than the age cutoff recommended for screening, but otherwise meet USPSTF criteria, have a similar risk of death to those individuals who meet all USPSTF criteria. Individuals in both subgroups could benefit from screening, as expansion of USPSTF screening criteria to include these subgroups could enable earlier detection of lung cancer and improved survival outcomes. FUNDING: National Institutes of Health and the Mayo Clinic Foundation.
引用
- Luo YH, Luo L, Wampfler JA, et al. 5-year overall survival in patients with lung cancer eligible or ineligible for screening according to US Preventive Services Task Force criteria: a prospective, observational cohort study. Lancet Oncol. 2019. PMID: 31255490. doi:10.1016/S1470-2045(19)30329-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。